HC Wainwright Creates Bullish Pitch On 4D Molecular Citing 'Broader Systemic Potential'

  • HC Wainwright has initiated coverage on 4D Molecular Therapeutics Inc FDMT with a price target of $36 and a Buy rating.
  • The analyst lists the following reasons for being bullish on the stock.
    • The analyst believes R100 intravitreal vector delivery in wet age-related macular degeneration patients could define a paradigm shift in available therapies, specifically in the context of SOC repeat intravitreal injections of anti-VEGF therapy.
    • With the vector pipeline spanning ophthalmology, cardiology, pulmonology, and vector transport by multiple delivery methods, HC Wainwright believes there are multiple opportunities for optimized vector targeting.
    • The analyst highlights supportive interim results from the ongoing Phase 1/2 trial.
    • Recently, the company announced interim clinical data from cohort 1 of the Phase 1/2 trial of intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD).
    • 4D-150 was safe and well tolerated, with no serious adverse events or dose-limiting toxicities reported.
  • Price Action: FDMT shares are up 1.85% at $22.82 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetInitiationSmall CapAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!